期刊文献+

血清酶在贫血性疾病中的表达及意义

下载PDF
导出
摘要 目的观察血清乳酸脱氢酶(LDH)、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)和碱性磷酸酶(ALP)在再生障碍性贫血(AA)、缺铁性贫血(IDA)、巨幼细胞贫血(MA)、溶血性贫血(HA)、骨髓增生异常综合征(MDS)中的活性变化,并探讨其意义。方法将155例贫血性疾病患者根据所患疾病的不同分为AA组29例、IDA组38例、MA组29例、HA组32例及MDS组27例。另选取正常健康人30例作为对照组。使用美国贝克曼LX20全自动生化分析仪检测AA、IDA、MA、HA、MDS、对照组中的LDH、ALT、AST、ALP等酶的活性度。结果 MA、HA、MDS组中LDH水平明显高于对照组(P<0.05),AA组LDH水平低于对照组(P<0.05)。各组ALT、AST、ALP水平比较差异均无统计学意义(P>0.05)。结论血清酶检测简便、易行,患者接受程度高,在临床工作中,对于贫血性疾病的鉴别有一定的指导意义。
出处 《临床合理用药杂志》 2012年第13期128-129,共2页 Chinese Journal of Clinical Rational Drug Use
基金 河北省卫生厅立项课题(No:20110291)
关键词 贫血 血清酶 诊断
  • 相关文献

参考文献5

二级参考文献20

  • 1Varma N, Varma S. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes. Indian J Pathol Microbiol, 2008 ;51 ( 1 ) :97 - 101.
  • 2Murphy PT, McPherson S, Breen K, et al. Serum erythropoietin at diagnosis in low grade myelodysplastic syndrome correlates with both red cell zinc protoporphyrin and serum lactic dehydrogenase (LDH) and may reflect severity of ineffective erythropoiesis. Leuk Lymphoma, 2009 ;50(6) : 1036 - 1038.
  • 3Malcovati L, Germing U, Kti ndgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol, 2007; 25 (23) : 3503 -3510.
  • 4Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997; 89(6): 2079-2088.
  • 5Aul C, Gattermann N, Heyll A, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia, 1992; 6 (1): 52-59.
  • 6Wimazal F, Sperr WR, Kundi M, et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res,2001; 25(4): 287-294.
  • 7Germing U, Hildebrandt B, Pfeilstocker M, et al. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia, 2005; 19( 12): 2223-2231.
  • 8Aul C, Gattermann N, Germing U, et al. Risk assessment in primary myelodysplastic syndromes: validation of the DUsseldorf score. Leukemia, 1994 ; 8 ( 11 ) : 1906 - 1913.
  • 9Sperr WR, Wimazal F, Kundi M, et al. Survival analysis and AML development in patients with de novo myelodysplastic syndromes : comparison of six different prognostic scoring systems. Ann Hematol, 2001; 80(5) :272 -275.
  • 10Gonzalez-Medina I, Bueno J, Torrequebrada A, et al. Two groups of chronic myelomonocytic leukaemia : myelodysplastic and myeloproliferative. Prognostic implications in a series of a single center. Leuk Res, 2002 ; 26 (9) : 821 - 824.

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部